Schnorr D, Kelly L U, Guddat H M, Schubert J, Gorski J, Schorcht J, Mau S, Wehnert J
Z Urol Nephrol. 1983 Dec;76(12):753-61.
High-voltage therapy is becoming increasingly important as a form of individual differential therapy of carcinoma of the prostate. Around 40% of all patients with a diagnosis of carcinoma of the prostate can be treated with high-voltage therapy. The precondition is the absence of bone and soft-tissue metastases and of juxtaregional lymph-node metastases. Individual carcinoma therapy is based on pre-therapeutic tumor classification according to the TNM system. The 5-year survival rates are presented from a retrospective study carried out using primary radiation monotherapy and a combined hormone and radiation therapy; these figures were calculated by the life-table method. The study revealed no significant differences between the two forms of therapy as regards 5-year survival rates. The 5-year survival rates of all patients of the classifications T0-T3Nx-N2M0 irradiated (n: 198) (72% +/- 11% for hormone plus radiation therapy and 74% +/- 11% for radiation monotherapy) did not differ greatly from those of a normal male population of the same age (77%). High-voltage therapy of carcinoma of the prostate can thus be classified as a curative method of treatment.
作为前列腺癌个体化差异治疗的一种形式，高压疗法正变得越来越重要。在所有被诊断为前列腺癌的患者中，约40%可以接受高压疗法治疗。前提是不存在骨和软组织转移以及区域旁淋巴结转移。个体化癌症治疗基于根据TNM系统进行的治疗前肿瘤分类。5年生存率来自一项回顾性研究，该研究采用了单纯放射治疗和激素与放射联合治疗；这些数据通过寿命表法计算得出。该研究显示，在5年生存率方面，两种治疗形式之间没有显著差异。所有T0 - T3Nx - N2M0分期接受放疗的患者（n：198）（激素加放疗组为72%±11%，单纯放疗组为74%±11%）的5年生存率与同年龄正常男性人群的5年生存率（77%）相比差异不大。因此，前列腺癌的高压疗法可被归类为一种治愈性治疗方法。
